KV9.3 Antibody (D-6): sc-365979

KV9.3 Antibody (D-6) is a mouse monoclonal IgG1 kappa light chain antibody that detects KV9.3 protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). KV9.3 (D-6) antibody is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. KV9.3 protein plays a crucial role in regulating potassium ion flow across the plasma membrane, which is essential for maintaining electrical excitability of neurons and muscle cells. KV9.3 is part of the voltage-gated potassium channel family, which is responsible for repolarizing membrane potential after action potentials, thereby influencing frequency and duration of neuronal firing. KV9.3 subunit specifically modulates channel activity, reducing ion flow and contributing to fine-tuning of excitability in various tissues. KV9.3 is predominantly expressed in lung, with minimal presence in peripheral blood lymphocytes, highlighting specialized function in respiratory physiology. Anti-KV9.3 antibody (D-6) effectively detects this target across multiple species and applications, making KV9.3 (D-6) monoclonal antibody an invaluable tool for researchers studying ion channel dynamics and their implications in health and disease.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

KV9.3 Antibody (D-6) References:

1. Heteromeric assembly of Kv2.1 with Kv9.3: effect on the state dependence of inactivation.  |  Kerschensteiner, D. and Stocker, M. 1999. Biophys J. 77: 248-57. PMID: 10388754
2. Electrically silent potassium channel subunits from human lens epithelium.  |  Shepard, AR. and Rae, JL. 1999. Am J Physiol. 277: C412-24. PMID: 10484328
3. Subunit composition determines Kv1 potassium channel surface expression.  |  Manganas, LN. and Trimmer, JS. 2000. J Biol Chem. 275: 29685-93. PMID: 10896669
4. Structural determinants of the regulation of the voltage-gated potassium channel Kv2.1 by the modulatory α-subunit Kv9.3.  |  Kerschensteiner, D., et al. 2003. J Biol Chem. 278: 18154-61. PMID: 12642579
5. Different Kv2.1/Kv9.3 heteromer expression during brain and lung post-natal development in the rat.  |  Coma, M., et al. 2002. J Physiol Biochem. 58: 195-203. PMID: 12744302
6. Fluorescence measurements reveal stoichiometry of K+ channels formed by modulatory and delayed rectifier alpha-subunits.  |  Kerschensteiner, D., et al. 2005. Proc Natl Acad Sci U S A. 102: 6160-5. PMID: 15827117
7. Stromatoxin-sensitive, heteromultimeric Kv2.1/Kv9.3 channels contribute to myogenic control of cerebral arterial diameter.  |  Zhong, XZ., et al. 2010. J Physiol. 588: 4519-37. PMID: 20876197
8. Silencing of voltage-gated potassium channel KV9.3 inhibits proliferation in human colon and lung carcinoma cells.  |  Lee, JH., et al. 2015. Oncotarget. 6: 8132-43. PMID: 25924237
9. The brain Kv1.1 potassium channel: in vitro and in vivo studies on subunit assembly and posttranslational processing.  |  Deal, KK., et al. 1994. J Neurosci. 14: 1666-76. PMID: 8126562
10. Immunohistochemical localization of five members of the Kv1 channel subunits: contrasting subcellular locations and neuron-specific co-localizations in rat brain.  |  Veh, RW., et al. 1995. Eur J Neurosci. 7: 2189-205. PMID: 8563969
11. Kv2.1/Kv9.3, a novel ATP-dependent delayed-rectifier K+ channel in oxygen-sensitive pulmonary artery myocytes.  |  Patel, AJ., et al. 1997. EMBO J. 16: 6615-25. PMID: 9362476
12. Coexpression of the KCNA3B gene product with Kv1.5 leads to a novel A-type potassium channel.  |  Leicher, T., et al. 1998. J Biol Chem. 273: 35095-101. PMID: 9857044

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-KV9.3 Antibody (D-6) has 0 citations in a variety of scientific publications.

Primary antibodies like Anti-KV9.3 Antibody (D-6) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

KV9.3 Antibody (D-6) Specifications

Alternate Product Name: KV9.3

Product Clone Name: D-6

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids: 411-491

Epitope Target: KV9.3

Epitope Species: human

Product Reactivity/Detection: KV9.3

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, ELISA

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 0 citations in various scientific publications

Available Conjugates/Forms for KV9.3 Antibody (D-6): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin